+ Watch CBST
on My Watchlist
A biopharmaceutical company focused on the research, development and commercialization of pharmaceutical products that address unmet medical needs in the acute care environment.
Comically simple speculation approach - buying the rumor, hoping to sell the news. I like Cubist a lot, but I'll hit the high points.*Rumored offer by Shire is probably legit, and will stir up BD execs at many other companies to take a peek. Confusingly, the articles all say the private offer was $44.5/share, or $2B, but with just shy of 60M shares outstanding it seems like that would be more in the $2.7B range. Current cap is $2.28B. A takeunder seems very unlikely, although they could be backing out CBST's debt when they cite the $2B figure, but with a big chunk of assets on their balance sheet as well I'm guessing the $2B is off substantially.*Cubicin offers a way to buy revenues over a stretch of time when many companies will have a gap due to the patent cliff (cubicin IP expires mid-2016).*Lots of upside to this company, including a seasoned ID sales force, some interesting pipeline products, and profitability.
BATS data provided in real-time. NYSE, NASDAQ and NYSEMKT data delayed 15 minutes.
Real-Time prices provided by BATS. Market data provided by Interactive Data.
Company fundamental data provided by Morningstar. Earnings Estimates, Analyst Ratings and Key Statistics provided by Zacks.
SEC Filings and Insider Transactions provided by Edgar Online.
Powered and implemented by Interactive Data Managed Solutions. Terms & Conditions